fbpx
  • MCRI: T CELL IMMUNOTHERAPY

MCRI: Dr. Ivan Borrello of Johns Hopkins Medicine, MILs Immunotherapy2018-07-13T00:15:48-06:00

Dr. lvan Borrello

Dr. Ivan Borrello, MD, PhD of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, is working to create a patient-specific immunotherapy using enhanced T cells from the patient’s own bone marrow, for truly personalized medicine.

Donate Today

How it Works: 

  • Some marrow infiltrating lymphocytes (a type of T cell) are extracted from a patient’s bone marrow during a biopsy
  • The MILs are then grown up 100x in the presence of the patient-specific myeloma cells in the laboratory. This trains the immune system cells to recognize potentially hundreds of myeloma “types” for that individual patient.
  • Autologous transplant is given.
  • Three to four days after transplant, the MILs are then given back. When they are re-introduced, they target the hundreds of proteins that could be causing tumor growth for that patient, not just a single protein and the T cells do their job to seek and destroy bad cells.
  • Because transplant wipes out lymphocytes and they naturally regrow, performing the transplant makes room for the engineered cells to doubly expand to reach their normal levels.
  • The research is already in Phase II clinical trials for patients with high risk genetic features.
  • Lenalidomide maintenance is then used as follow-up for anti-myeloma effects and immune system boosting

To learn more about this important project, read or listen to the Myeloma Crowd Radio Interview with Dr. Borrello.

MYELOMA CROWD RESEARCH INITIATIVE
$165328 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: